Total Payments
$2,779
2024 Payments
$789.78
Companies
19
Transactions
156
Medicare Patients
837
Medicare Billing
$99,608
Payment Breakdown by Category
Food & Beverage$2,779 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,779 | 156 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,375 | 74 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $306.08 | 21 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $234.37 | 13 | $0 (2024) |
| ITI, Inc. | $119.66 | 7 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $115.45 | 6 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $112.51 | 6 | $0 (2023) |
| Vanda Pharmaceuticals Inc. | $109.35 | 7 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $80.49 | 4 | $0 (2022) |
| Alkermes, Inc. | $78.88 | 4 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $48.82 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $789.78 | 41 | ABBVIE INC. ($416.73) |
| 2023 | $989.98 | 48 | ABBVIE INC. ($701.85) |
| 2022 | $613.93 | 45 | ABBVIE INC. ($256.05) |
| 2021 | $320.69 | 18 | Janssen Pharmaceuticals, Inc ($89.23) |
| 2020 | $65.03 | 4 | Allergan, Inc. ($20.43) |
All Payment Transactions
156 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $26.11 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.95 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $22.71 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/31/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.68 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: Neuropsychiatry | ||||||
| 10/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.66 | General |
| Category: NEUROSCIENCE | ||||||
| 09/23/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $19.77 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 09/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $4.09 | General |
| Category: PSYCHIATRY | ||||||
| 08/27/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $21.15 | General |
| Category: Neuroscience | ||||||
| 08/15/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $4.56 | General |
| Category: PSYCHIATRY | ||||||
| 08/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $10.16 | General |
| Category: PSYCHIATRY | ||||||
| 07/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.93 | General |
| Category: NEUROSCIENCE | ||||||
| 06/28/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: NEUROSCIENCE | ||||||
| 06/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.04 | General |
| Category: NEUROSCIENCE | ||||||
| 06/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: NEUROSCIENCE | ||||||
| 05/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.41 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.50 | General |
| Category: NEUROSCIENCE | ||||||
| 05/20/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: PSYCHIATRY | ||||||
| 05/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.27 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 164 | 306 | $53,969 | $19,630 |
| 2022 | 5 | 224 | 450 | $61,504 | $28,571 |
| 2021 | 5 | 247 | 544 | $68,057 | $33,976 |
| 2020 | 3 | 202 | 370 | $31,356 | $17,431 |
Total Patients
837
Total Services
1,670
Medicare Billing
$99,608
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 140 | $24,624 | $8,028 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 73 | $13,672 | $4,954 | 36.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 59 | $7,675 | $3,427 | 44.6% |
| 90837 | Psychotherapy, 1 hour | Office | 2023 | 15 | 21 | $5,502 | $2,321 | 42.2% |
| 90834 | Psychotherapy, 45 minutes | Office | 2023 | 11 | 13 | $2,496 | $900.36 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 104 | 255 | $34,586 | $17,461 | 50.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 31 | 31 | $6,750 | $3,389 | 50.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 55 | $8,080 | $2,789 | 34.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 36 | 81 | $4,374 | $2,267 | 51.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 14 | 14 | $4,650 | $1,666 | 35.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 14 | $3,064 | $998.40 | 32.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 101 | 264 | $34,188 | $17,740 | 51.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 48 | 48 | $10,050 | $5,860 | 58.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 44 | 147 | $7,938 | $4,193 | 52.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 54 | $7,983 | $2,677 | 33.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 20 | 20 | $6,200 | $2,639 | 42.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 11 | $1,698 | $867.24 | 51.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 109 | 228 | $17,274 | $8,568 | 49.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 59 | 59 | $9,600 | $6,369 | 66.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 34 | 83 | $4,482 | $2,493 | 55.6% |
About Dr. Brian Howard, DO
Dr. Brian Howard, DO is a School healthcare provider based in Searcy, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/15/2016. The National Provider Identifier (NPI) number assigned to this provider is 1679934871.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Howard, DO has received a total of $2,779 in payments from pharmaceutical and medical device companies, with $789.78 received in 2024. These payments were reported across 156 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($2,779).
As a Medicare-enrolled provider, Howard has provided services to 837 Medicare beneficiaries, totaling 1,670 services with total Medicare billing of $99,608. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty School
- Other Specialties Psychiatry
- Location Searcy, AR
- Active Since 03/15/2016
- Last Updated 11/18/2020
- Taxonomy Code 103TS0200X
- Entity Type Individual
- NPI Number 1679934871
Products in Payments
- VRAYLAR (Drug) $1,367
- REXULTI (Drug) $247.40
- INVEGA SUSTENNA (Drug) $162.62
- CAPLYTA (Drug) $160.59
- INGREZZA (Drug) $115.45
- QELBREE (Drug) $112.51
- HETLIOZ (Drug) $109.35
- ABILIFY MAINTENA (Drug) $65.26
- ARISTADA (Drug) $58.39
- TRINTELLIX (Drug) $53.82
- COBENFY (Drug) $48.82
- SPRAVATO (Drug) $42.41
- Dyanavel XR (Drug) $33.13
- INVEGA TRINZA (Drug) $29.34
- VYVANSE (Drug) $26.67
- VIVITROL (Drug) $20.49
- JORNAY PM (Drug) $19.77
- UZEDY (Drug) $17.07
- NUEDEXTA (Drug) $14.56
- QUVIVIQ (Drug) $13.75
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.